NCT05621447 is a Phase 1 clinical trial of TAS-303, [14C]TAS-303 in Healthy Male Subjects, sponsored by Taiho Pharmaceutical Co., Ltd..

Who is sponsoring NCT05621447?

NCT05621447 is sponsored by Taiho Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05621447?

Interventions in NCT05621447: TAS-303, [14C]TAS-303.

What condition does NCT05621447 study?

NCT05621447 studies Healthy Male Subjects.

Is NCT05621447 still recruiting?

NCT05621447 is currently completed. Last updated 7 August 2023.

Last reviewed 2023-08-07 · How we verify

NCT05621447

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

Completed Phase 1 Last updated 7 August 2023

What this trial tests

Phase 1 trial testing TAS-303, [14C]TAS-303 in Healthy Male Subjects in 6 participants. Completed in 22 February 2023.

Timeline

7 September 2022

Primary endpoint
3 November 2022

22 February 2023

Quick facts

Lead sponsor	Taiho Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	7 September 2022
Primary completion	3 November 2022
Estimated completion	22 February 2023
Sites	1 location across Japan

Drugs / interventions tested

TAS-303, [14C]TAS-303 — full drug profile →

Conditions studied

Healthy Male Subjects — all drugs for Healthy Male Subjects →

Sponsor

Taiho Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 40, male only, with Healthy Male Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of \[14C\]TAS-303 following oral single dose

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Male Subjects

Currently open trials in the same condition.

NCT07340476 — A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects · Phase 1 · active not recruiting

Other Taiho Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT05691660 — A Study of TAS3731 in Healthy Adults · Phase 1 · completed
NCT05335499 — A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria · Phase 2 · completed
NCT04825431 — Mass Balance Study of [14C] TAS-205 in Healthy Volunteers · Phase 1 · completed
NCT04512053 — A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence · Phase 2 · completed
NCT03605251 — Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis. · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05621447 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taiho Pharmaceutical Co., Ltd.
Last refreshed: 7 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05621447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing